The extramural research community is invited to compete for grant application funding to perform research and development in Cancer Imaging, which is prominent in the list of Extraordinary Opportunities that the National Cancer Institute (NCI) currently recognizes as likely to yield significant gains in public health. Through its Biomedical Imaging Program (BIP), NCI offers grant support for advances in medical imaging technologies applicable to cancer and pre-cancer research, screening, diagnosis, treatment, and monitoring of treatment progress. Many investigators are familiar with generic NIH Program Announcements to which they may submit investigator-initiated grant applications that support missions of the NIH Institutes and Centers (ICs). However, fewer know about specific grant application initiatives by individual ICs. Active NCI Imaging Initiatives administered by BIP are listed on its website, http://cancer.gov/bip. The short descriptions include additional web-links that lead directly to full-text Program Announcements that provide comprehensive information for investigators who wish to respond with applications. Current initiatives include Exploratory/Developmental Grants for Diagnostic Cancer Imaging (R21), Development of Novel Imaging Technologies (Phased Innovation Award-R21/R33), and Development of Novel Imaging Technologies (SBIR/STTR-R43/R44 and R41/R42). Domestic and foreign investigators from academia, research organizations, and large and small businesses are invited to check specific eligibility requirements found in the details of each program announcement. Investigators contemplating multi-disciplinary imaging technology development projects are encouraged to assemble teams that include necessary expertise either through direct participation or with collaborations and/or sub-contracts, as needed. Brief descriptions of older Program Announcements that are now closed are provided to show the range of initiatives supported by the Biomedical Imaging Program in the recent past. New NCI imaging initiatives are under consideration.
Introduction
The yield from the USA's decades long and continuing commitment to research in biology and medicine includes wonderful tools and knowledge gained on the workings of the things of life, health, and its mechanisms of failure. It is now known that cancer is the result of significant accumulations of failures in the pathways that control normal tissue growth, maintenance and cell replacement. Imaging developments expand our capabilities to detect, interpret, diagnose, and follow smaller and earlier changes in the processes of cell transformation from healthy tissues through dysplasia to malignancy and metastatic disease. The National Cancer Institute prepares annual budget requests and justifications for the President to submit to Congress, and these include requests for substantial funds to support competitively selected grant applications from research organizations external to the NCI. The NCI also makes use of external advisory groups to help health, and then develops initiatives to stimulate interest and progress in them.
NCI's Congressional Budget Request for Fiscal Year 2002
In his Director's Message to the National Cancer Institute's Fiscal Year 2002 Budget plan, Dr. Richard Klausner, M.D., wrote about the accelerating pace of scientific discovery, and how the excitement generated by this new atmosphere of discovery is evident in cancer research [see http://plan2002.cancer.gov/brdirector.htm for the complete statement].
He cites progress in three evolving areas, and the role of imaging is self-evident in two of them:
The explosion of information on the fundamental nature of cancer, and the promise it offers for improving our ability to target prevention measures, to detect cancers early while they are most curable, and to develop treatments that are individually targeted for maximum results with the fewest side effects.
Development of new tools and approaches for conducting clinical research, along with novel imaging technologies, allow us to view activity at the molecular level. The use of workstations with high-resolution medical image displays enables real-time medical consultation from multiple locations around the world. Information management tools allow investigators to collect and analyze patient data in a more efficient fashion. All of these advances are enabling us to answer important clinical questions more rapidly, accurately, and effectively.
Growing sophistication in behavioral and population research allows us to understand and address the burden of cancer.
Dr. Klausner's budget message notes that underlying these three areas of progress are several key changes in the overall research enterprise:
We are witnessing and facilitating a fundamental change in the way scientific discovery is accomplished. Advances in our understanding of cancer at the molecular level, coupled with technologies drawn from the chemical, physical, and material sciences are enabling us to approach our research with a greater sense of predictability and precision. We are now able to move from empiric, fact-finding studies to "designed" research in which we identify a range of compelling options for prevention, detection, diagnosis, and treatment; verify their efficacy using models and electronic tools; and validate them through extensive testing and clinical trials. This fundamental change in how we approach research maximizes the effectiveness of all areas of scientific discovery, from broad-based science with potential to benefit all types of cancer to "disease-based" studies that focus on specific types of cancer.
We are seeing an increasing amount of research that brings together and melds different scientific perspectives and the tools of multiple disciplines. For example, by integrating the work of epidemiologists, geneticists, and population scientists, we hope to better understand the potential interplay among inherited susceptibility, lifestyle, and exposure to environmental pollutants and infectious agents in cancer causation. By combining the efforts of engineering technology and biomedical science, we have been able to devise highly sophisticated imaging tools for detecting, diagnosing, and even aiding in the treatment of cancer patients.
Our ability to do research on a large scale and with greater complexity has increased significantly. For instance, the development of common forms, terminology, and reporting requirements for use in cancer clinical trials is increasing the speed, efficiency, and accuracy of results, reporting and analysis. We are also able to store and disseminate data on thousands of tumor tissue samples, making the data available to researchers around the world.
NCI's Biomedical Imaging Program Initiatives
The Biomedical Imaging Program (BIP), part of NCI's Division of Cancer Treatment and Diagnosis, participates actively in support of the Extraordinary Opportunity in Cancer Imaging. Since new imaging technologies and methods allow us to see vital body processes as they take place, let us find cancers earlier, and treat them more effectively, BIP places significant emphasis on supporting the development of advances in imaging technologies and methods. These include hardware, and also increasingly important efforts in algorithms, software and computer science that enable an expanding array of functions and capabilities-from machine control to processing of raw data into images, analysis of single images, registration of multiple images and their analysis, localization and detection of normal and abnormal anatomical, molecular and functional features, image interpretations, computer assisted diagnosis, treatment planning and image guided therapy, monitoring of therapeutic progress, image archiving systems and databases, and other software tools with which to glean knowledge, improve understanding, and enhance applications of the available data to the improvement of individual and public health.
Biomedical Imaging Program's Open Initiatives
From the BIP website, http://cancer.gov/bip, one can use the title line of each of the following short descriptions to link directly to the actual program announcement, where full details may be found. PAR-01-101 and PAR-01-102, second and third listings below, are paired initiatives to develop innovative imaging technologies. The first is for any eligible applicant organization (university, large or small business, research institute, some government laboratories, etc.), and the second is reserved for USA small businesses. One committee reviews all the applications submitted in response to both announcements. The background experience of reviewers recruited to that committee emphasizes technology and methods developers, rather than experience solely as users.
NCI/BIP: PA-01-030: Exploratory/Developmental Grants for Diagnostic Cancer Imaging (R21s): The Biomedical Imaging Program (BIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) grants that articulate highly innovative research concepts in diagnostic cancer imaging. Within each area of importance in imaging, there exists a need for innovative and creative approaches leading to new avenues of research. One way to encourage research into high risk/high impact areas is to provide investigators with the initial resources required to accomplish feasibility and pilot testing of innovative ideas. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial feasibility testing of high risk/high impact concepts and, if the concepts are viable, for the generation of experimental preliminary data. This would render the investigators competitive for continued funding through other NIH research award mechanisms, thus potentially leading to the establishment of new research programs in areas that might have previously remained unexplored. Award) : The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to develop novel image acquisition or enhancement methods, and incorporate limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the development of novel imaging technologies for early detection, screening, diagnosis, and image guided treatment of cancer and other diseases. The intent is to stimulate (a) the development of innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. A phased innovation award mechanism (R21/R33) is proposed that is more suitable for supporting imaging technology development. Applications from academia, industry, and independent research organizations are encouraged. Modifications to this reissued Program Announcement include support for a limited number of system prototypes for pilot or feasibility evaluations using either pre-clinical models or clinical studies. Small business applicants are encouraged to apply under the following announcement, PAR-01-102.
Release Date: May 29, 2001
Letter of Intent Receipt Dates: June 11, 2001 , February 11, 2002 and June 11, 2002 Application Receipt Dates: July 16, 2001 and March 18, 2002 , and July 16, 2002 No set aside funds. Contact: Houston Baker at hb4s@nih.gov or Laurence Clarke at lclarke@mail.nih.gov.
NCI/BIP: PAR-01-102: Development of Novel Imaging Technologies (Phased Innovation Award) (SBIR/STTR):
The National Cancer Institute (NCI), National Institute of Environmental Health Sciences (NIEHS), and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications from small businesses to develop novel image acquisition or enhancement methods, and incorporate limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is to facilitate small business developments of novel imaging technologies for early detection, screening, diagnosis and image guided treatment of cancer and other diseases. The intent is to stimulate (a) the development of innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. The two mechanisms used are the Small Business Innovation Research Award (R43/R44), and the Small Business Technology Transfer Award (R41/R42) for collaborations by independent research organizations with small businesses. Details are provided in the full Program Announcement. Modifications to the reissue of this Program Announcement include support for a limited number of system prototypes for pilot or feasibility evaluations using either pre-clinical models or clinical studies, and use of joint ven-tures for SBIR/STTR's. Applicants not meeting small business requirements are encouraged to apply under the foregoing announcement, PAR-01-101.
Release Date: May 29, 2001 Letter of Intent Receipt Dates: June 11, 2001 , February 11, 2002 and June 11, 2002 Application Receipt Dates: July 16, 2001 and March 18, 2002 , and July 16, 2002 No set aside funds Contact: Houston Baker at hb4s@nih.gov or Laurence Clarke at lclarke@mail.nih.gov.
The following initiative for grant applications on digital mammography is expired, but interested parties may submit investigator-initiated applications on this subject under the Omnibus Solicitation for the SBIR/STTR Programs, a regular NIH R01 application, or any of the three BIP open initiatives above. The Biomedical Imaging Program (BIP), Division of Cancer Diagnosis and Treatment (DCTD), National Cancer Institute (NCI) plans to develop contracts to support Phase 1 (Safety) and Phase 2 (Preliminary Clinical Efficacy) clinical trials of promising imaging agents. These clinical trials will be used to rapidly evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI. The Safety and Preliminary Clinical Efficacy Imaging Clinical Trials contracts will create an infrastructure poised to rapidly evaluate molecularly-targeted imaging agents used to assess therapeutic anticancer agents on their molecular targets and determine clinically relevant correlates. The objectives of this program are to rapidly conduct clinical trials necessary to assess the safety of promising imaging agents;
to rapidly conduct clinical trials necessary to assess the diagnostic imaging capabilities and preliminary efficacy of a promising imaging agent to characterize the molecular interactions of new molecular imaging agents with their targets through biopsies, assays, and other appropriate technologies and correlate those effects with clinically-relevant endpoints; to develop new scientific insights into molecular pathways and determinants of the relationship of the targeted imaging agents to therapeutic drug response. Major emphasis shall be on imaging agents that are found to be safe and which provide important structural, metabolic, or molecular imaging data that will be important and useful in the management of patients with cancer. These Phase 1 and Phase 2 clinical trials will obtain data necessary to fulfill the Food and Drug Administration (FDA) criteria to eventually become an approved and potentially marketable imaging agent for specific imaging indications. The studies will explore promising imaging agents, and require rapid initiation, completion, and data reporting. These contracts will also require the ability to implement correlative studies validating the localization of the investigational imaging agents on their molecular target in tumors. Imaging agents may originate from investigators not affiliated with clinical sites. The Government anticipates that five (5) contracts will be awarded on an incrementally funded basis for five years. The size of each trial might vary depending on consultation with the FDA for each specific agent. The typical size for each Safety trail will be approximately 10 patients. The typical size for each Preliminary Clinical Efficacy trail is estimated to be 25 patients. NAICS Code No. 621512 with a size standard of $5.Million. Kathy Giuliano, Contract Specialist, Email: kg109o@nih.gov MaryAnne Golling, Contracting Officer, Email: mg345x@nih.gov 
Points of Contact

Biomedical Imaging Program's Closed Initiatives
Program Announcements that are now closed represent areas of special interest in the recent past.
(Closed contract solicitation) Number N01-CM-17004-28: Ultrasound Research Interface: The intent of this proposed RFP is to develop powerful ultrasound research interfaces that allow extensive control over a wide range of system parameters. These interfaces will be software add-ons to continuously evolving scanner control software. The interface software could run either on the current ultrasound com-puter systems, or on stand-alone computer systems (PC's) interfaced to the ultrasound scanner control. Although the creation of these interfaces necessarily relies on access to proprietary information, such access can be partly restricted by protective software shells, while still accessing the control parameters. The intent of this concept is to allow research interfaces to be developed by several leading ultrasound manufacturers to maximize the research impact for the ultrasound imaging community. (Closed Program Announcement) NCI/BIP: RFA: CA-01-010: Planning Grants: In Vivo Cellular and Molecular Imaging Centers (Pre-ICMIC P20 Center Grants): Grants are designed to support inter-disciplinary centers for functional imaging research (imaging sciences, chemistry, radiopharmaceutical chemistry, cell and molecular biology, pharmacology, computer science and biomedical engineering).
(Closed Program Announcement) NCI/BIP: RFA: CA-01-001: Lung Imaging Database Resource for Imaging Research: The National Cancer Institute (NCI) invites applications from investigators who are interested in joining a consortium of institutions to develop the necessary consensus and standards for an image database resource and to construct a database of spiral computed tomography (CT) lung images. There is considerable interest in using spiral CT lung scanning for lung cancer screening for patients at high risk.
Early detection and intervention may significantly reduce lung cancer mortality rates. The use of image processing methods may be an important adjunct to facilitate spiral CT lung cancer screening. Investigators developing image-processing algorithms need standardized databases with which to work. The generation of standardized databases requires the development of consensus on many issues related to database design, accessibility, metrics and statistical methods for evaluating image-processing algorithms. NCI therefore plans to establish a consortium of institutions, called the Lung Image Database Consortium (LIDC), to develop such consensus and the necessary database.
(Closed Program Announcement) NCI/BIP RFA: CA-98-024: Development and Application of Imaging In Therapeutic Studies: Support for development and application of labeled therapeutic agents as compounds for imaging studies, and/or metabolic markers of response to therapeutic agents.
(Closed Program Announcement) NCI/BIP: RFA CA-99-015 / PAR -99-149 (SBIR/STTR): Diagnostic Imaging and Guided Therapy in Prostate Cancer. Phased Innovation Award (R21/R33). Grants are designed to support the development, risk assessment, and application of improved imaging methods for the localization, biopsy and image guided biopsy or therapy of prostate cancer. Relevant investigations could include technology development, in vitro laboratory work, pre-clinical animal studies, or early feasibility testing in humans depending on the maturity of the methods proposed, or evaluation of the effects of age-associated changes and co-morbid conditions as they affect imaging diagnosis and treatment techniques.
